CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering.

OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the “Rights Offering”).

Pursuant to the Rights Offering, the Company is distributing to all holders of record of the Company's common stock, par value $0.001 per share (“Common Stock”), and to holders of certain options and warrants that have the right to participate in the Rights Offering (the “Participating Securities”), as of 5:00 p.m., Eastern Time, on February 10, 2026 (the “Record Date”), at no charge, non-transferable subscription rights (the “Subscription Rights”) to purchase up to an aggregate of 12,000 units (“Units”) at a subscription price of $1,000 per whole Unit.

Each holder of the Company's Common Stock or Participating Securities will receive one Subscription Right for every share of Common Stock (including each share of Common Stock issuable upon conversion of Participating Securities) owned on the Record Date. Each Subscription Right will entitle its holder to purchase one Unit, each Unit consisting of one share of Series G Convertible Preferred Stock (the “Preferred Stock”), and 1,666 warrants to purchase Common Stock (the “Warrants”) at a subscription price of $1,000 per Unit. Each share of Preferred Stock will be convertible, at the option of the holder at any time, into 833 shares of Common Stock, which is equal to the quotient of the stated value of the Preferred Stock ($1,000) divided by the conversion price ($1.20 per share). Each Warrant will be exercisable for one share of Common Stock at an exercise price of $1.20 per share from the date of issuance through its expiration five years from the date of issuance. No fractional Subscription Rights are being distributed and no fractional Units will be issued upon the exercise of any Subscription Rights in the Rights Offering. Stockholders must exercise Subscription Rights for at least one whole Unit to participate in the Rights Offering. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering. The Company may extend the period for exercising the Subscription Rights. Subscription Rights which are not exercised by the expiration date of the Rights Offering will expire and will have no value.

Assuming the Rights Offering is fully subscribed, the Company expects to receive aggregate gross proceeds of $12 million. Holders who fully exercise their basic Subscription Rights will be entitled to subscribe for additional Units that remain unsubscribed as a result of any unexercised basic Subscription Rights. If over-subscription privilege requests exceed the remaining Units available, the remaining Units will be allocated pro-rata among holders who over-subscribe based on the number of Common Stock held by all holders exercising the privilege.

The subscription period for the Rights Offering commenced on February 11, 2026 and will end at 5:00 p.m., Eastern Time, on February 27, 2026, unless extended by the Company (the “Subscription Period”). The Subscription Rights are non-transferable and will only be exercisable during the Subscription Period. Once holders have exercised their Subscription Rights, such exercise may not be revoked, canceled, or changed, even if holders subsequently learn information about the Company or its business, financial position, results of operations or cash flows that is material or adverse or that the holders otherwise consider to be unfavorable. The Company may cancel, modify or amend the Rights Offering at any time and for any reason prior to the expiration of the Subscription Period.